Heart Failure Clinical Trial

Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)

Summary

This study is being done to evaluate the safety and effectiveness of alagebrium in subjects diagnosed with diastolic heart failure. The primary assessment for effectiveness is the assessment of exercise tolerance.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

diagnosis of diabetes or hypertension requiring therapy
EF >/= 45% via echo within 1 year and evidence of diastolic heart failure via echo measurement of E/E'>/= 12 determined by echo within 1 year
previous hospitalization for heart failure or previous BNP >100 pg/mL.

Exclusion Criteria:

Clinically significant valvular disease
history of stroke/TIA or reversible ischemic neurological defect w/i 6 mths
history of acute MI within 6 months
severe COPD
active or treated malignancies (except basal cell carcinoma)
significant systemic illnesses that would prohibit completion of the study or compliance

Study is for people with:

Heart Failure

Phase:

Phase 2

Estimated Enrollment:

160

Study ID:

NCT00662116

Recruitment Status:

Terminated

Sponsor:

Synvista Therapeutics, Inc

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 28 Locations for this study

See Locations Near You


Birmingham Alabama, 35294, United States

Huntsville Alabama, 35801, United States

Mobile Alabama, 36608, United States

Anaheim California, , United States

Bakersfield California, 93308, United States

La Jolla California, 92037, United States

Roseville California, 95661, United States

Jacksonville Florida, 32209, United States

Miami Florida, 33136, United States

St. Petersburg Florida, 33709, United States

Covington Georgia, 30014, United States

Indianapolis Indiana, 46260, United States

Louisville Kentucky, 40207, United States

Auburn Maine, 04210, United States

South Portland Maine, 04106, United States

Ayer Massachusetts, 01432, United States

Lincoln Nebraska, 68506, United States

Ridgewood New Jersey, 07450, United States

Albany New York, 12205, United States

Stonybrook New York, 11794, United States

Winston-Salem North Carolina, 27157, United States

Cincinnati Ohio, 45219, United States

Dayton Ohio, 45414, United States

Fairfield Ohio, 45014, United States

Sandusky Ohio, 44870, United States

Oklahoma City Oklahoma, 73112, United States

Charleston South Carolina, 29401, United States

Germantown Tennessee, 38138, United States

Lackland Airforce Base Texas, , United States

Milwaukee Wisconsin, 53215, United States

How clear is this clinincal trial information?

Study is for people with:

Heart Failure

Phase:

Phase 2

Estimated Enrollment:

160

Study ID:

NCT00662116

Recruitment Status:

Terminated

Sponsor:


Synvista Therapeutics, Inc

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider